| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJHF.1857 |
| P698 | PubMed publication ID | 32432391 |
| P50 | author | Marco Metra | Q39274051 |
| P2093 | author name string | Milton Packer | |
| P2860 | cites work | Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 |
| Should β-blockers be used in patients with heart failure and atrial fibrillation? | Q28267603 | ||
| Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study | Q28291971 | ||
| A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure | Q28328342 | ||
| Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) | Q28378044 | ||
| Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis | Q30847905 | ||
| Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. | Q31383623 | ||
| Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. | Q33882750 | ||
| Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial | Q34069413 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan | Q34150300 | ||
| Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial | Q34213067 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 | ||
| 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society o | Q34556019 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 | ||
| Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial | Q34751971 | ||
| Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial | Q35668887 | ||
| Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial | Q37394083 | ||
| Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. | Q38074639 | ||
| Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial | Q38371833 | ||
| Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. | Q38805331 | ||
| Double Vision: Replicating a Trial Showing a Survival Benefit | Q39158517 | ||
| Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients | Q41710632 | ||
| Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure | Q42206347 | ||
| Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial | Q43239377 | ||
| Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study | Q43754680 | ||
| Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). | Q44806443 | ||
| Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure | Q49914014 | ||
| How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence | Q50167747 | ||
| Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis | Q50237679 | ||
| Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. | Q53612767 | ||
| Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology | Q56381075 | ||
| Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews | Q57174292 | ||
| The effect of digoxin on mortality and morbidity in patients with heart failure | Q73080377 | ||
| Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study | Q84106395 | ||
| Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial | Q88062743 | ||
| Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators | Q88083015 | ||
| Sacubitril-Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It? | Q88223879 | ||
| Does a Target Dose or a Target Heart Rate Matter to Outcomes When Prescribing β-Blockers to Patients With Chronic Heart Failure? | Q88286518 | ||
| New Evidence Supporting a Novel Conceptual Framework for Distinguishing Proportionate and Disproportionate Functional Mitral Regurgitation | Q89779198 | ||
| Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure | Q90109064 | ||
| Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | Q90176149 | ||
| Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry | Q90344844 | ||
| Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges | Q90404983 | ||
| Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | Q90718817 | ||
| Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry | Q91437197 | ||
| Risks of Intensive Treatment of Long-Standing Atrial Fibrillation in Patients With Chronic Heart Failure With a Reduced or Preserved Ejection Fraction | Q92151103 | ||
| Treatment of functional mitral regurgitation in chronic heart failure: can we get a 'proof of concept' from the MITRA-FR and COAPT trials? | Q92214656 | ||
| Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF | Q92604725 | ||
| Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry | Q92747485 | ||
| P921 | main subject | ejection fraction | Q641303 |
| P577 | publication date | 2020-05-20 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction |
Search more.